As blockbuster heart failure drug Entresto inches toward a patent cliff, Novartis is calling on the FDA—again—to keep early-bird generics at bay. At the time, Novartis argued greenlighting any generic ...
On July 15, 2025, Judge Evelyn Padin of the District of New Jersey denied Novartis’s motion for preliminary injunction, which would have blocked MSN Laboratories Pvt. Ltd. from selling a generic ...
Some people with heart failure need to take multiple medicines each day in order to keep their symptoms under control. Heart failure not only leads to issues in the heart but other organs in the body ...
Case Name: In re Entresto, 125 F.4th 1090 (Fed. Cir. Jan. 10, 2025) (Circuit Judges Lourie, Prost, and Reyna presiding; Opinion by Lourie, C.J.) (Appeal from D. Del ...
Novartis is already suing a long list of generics producers that aim to bring copycats of the company's popular heart failure drug Entresto to market. Now, the Swiss pharma itself has become target in ...
Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with Medicare ...
Novartis last year launched an unbranded campaign called Understanding Heart Failure. Novartis’ new heart-failure drug Entresto generated $21 million in sales in 2015, and the company attributed the ...
Novartis announced the publication of clinical data from a post-hoc analysis showing significant improvement in physical and social activities at 8 months with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback